Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients

  • STATUS
    Recruiting
  • End date
    May 25, 2023
  • participants needed
    100
  • sponsor
    Theralase Inc.
Updated on 25 May 2022

Summary

This is a phase II, open-label, single-arm, multi-center Study conducted in Canada, the United States and internationally. Patients with NMIBC CIS with or without resected papillary disease (Ta, T1) that are considered bacillus Calmette-Guerin (BCG)-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; OR, At least five of six doses of an initial induction course plus at least two of six doses of a second induction course. Patients experiencing disease relapse less than 12 months after finishing the second course of BCG therapy are also considered BCG-Unresponsive. The Study will consist of 100 patients who will undergo two (2) PDT treatments employing 0.70 mg/cm^2 of TLD-1433 at Day 0 and Day 180.

Description

  1. Overall Study Design and Plan: Description

This is a phase II, open-label, single-arm, multi-center Study conducted in Canada, the United States and internationally. Patients with NMIBC CIS with or without resected papillary disease (Ta, T1) that are considered BCG-Unresponsive or are intolerant to BCG therapy that meet the inclusion and exclusion criteria will be enrolled and treated. The Study will consist of 100 patients who will receive PDT employing 0. 70 mg/cm^2 (Therapeutic Dose).

2. Screening Period

Patients will be qualified for Study entry by review of inclusion and exclusion criteria during the Screening Period, which will last up to 45 days.

3. Follow-Up Phase

All patients enrolled and treated by the treatment procedure will be followed until the End of Study defined as completion of all required assessments after 15 months of follow-up post treatment or earlier due to early discontinuation or withdrawal of informed consent.

During the Follow-Up Phase, information on efficacy and safety will be collected. Assessments will be conducted at Day 0, 7, 30, 60, 90, 180, 187, 210, 240, 270, 360 and 450 days.

4. Study Drug and PDT Administration

TLD-1433 for intravesical administration is supplied as a lyophilisate for suspension in Sterile Water for Injection into the bladder and is packaged in the dark in amber USP Type III glass vials which can be stored at room temperature. Up to 24 hours before administration, it is reconstituted with Sterile Water for Injection to obtain the final clinical dilution.

TLD-1433 will be supplied to each Study site by Theralase. Instillations cannot be done immediately following biopsy taken by TURBT. Investigators must wait a minimum of 7 days before dosing patients after a TURBT/biopsy, and/or until any bladder wall integrity issues have resolved. Dose/volume reductions are not allowed during this Study.

Upon determination of the bladder volume (during the screening period) through a voiding diary or measuring instilled water volume, TLD-1433 to be instilled will be diluted to the proper concentration. On day 0 (treatment day), patients will be asked to restrict fluid intake 12 hours before Study Drug instillation. Study drug must be instilled into the patient's empty bladder. Before instillation, a regular transurethral catheter should be inserted and the bladder drained. A single instillation of TLD-1433 will be infused intravesically for approximately 60 minutes, followed by 3 washes with sterile water. The bladder will be distended using a fourth instillation of sterile water to prevent folds that may prevent uniform light illumination. The laser technician worksheet must be completed during the procedure and data must be promptly transferred to the corresponding electronic Case Report Form ("eCRF") page.

Insertion of the optical fiber with spherical diffuser into the bladder will be monitored under ultrasonic guidance. The optical fiber with spherical diffuser will be positioned in the geometric center of the bladder with the aid of TLC-3200 and will be locked into place using an endoscope holder for continuous irradiation for the total exposure time. Exposure time will be calculated based on power emitted from the end of the optic fiber. The optic fiber is inserted through a liquid-tight lock via a catheter into the urethra. The optical power and treatment time will be determined to provide the correct dose of laser light to the bladder surface area. Green laser light (wavelength = 532 nm, energy = 90 J/cm2) will be irradiated from the emitter optical fiber via the spherical diffuser. The bladder volume may be monitored during the procedure and water instilled or drained, as required, to keep the bladder volume as consistent as possible.

4.1 Dosing Schedule

Two treatment procedures are planned, a primary treatment at Day 0 and a secondary treatment at Day 180 post primary treatment. Each treatment procedure is a single whole bladder intravesical PDT with TLD-1433 and the TLC-3200 System.

4.2 PDT Disruption

Patients with persistent or recurrent NMIBC CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumour invades the subepithelial connective tissue) disease within 12 months of completion of BCG therapy (BCG-Unresponsive) or who are intolerant to BCG therapy will be treated with this Protocol. If one or more papillary tumours are seen at the time of Study Treatment (maximum 12 weeks after TURBT), the patient will be resected and will be treated with this Protocol.

Details
Condition Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Treatment TLD-1433 Bladder infusion and Photodynamic Therapy
Clinical Study IdentifierNCT03945162
SponsorTheralase Inc.
Last Modified on25 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Be willing and able to provide a written Informed Consent Form ("ICF") for the Study
Be > 18 years of age on day of signing ICF
Have histologically confirmed NMIBC CIS via biopsy with/without resected papillary disease (Ta, T1) (high grade) using the 2004 World Health Organization ("WHO") / International Society of Urologic Pathology classification system. The most recent cystoscopy / TURBT must have been performed within 12 weeks of the treatment date to confirm: histology, grade and stage
Intolerant to BCG or considered BCG-Unresponsive, which is at least one of the
following
At least five of six doses of an initial induction course, plus at least two of three doses of maintenance therapy, or
Have an Eastern Cooperative Oncology Group ("ECOG") performance score of 0 to 2
Are available for the duration of the Study including follow-up (approximately 15 months)
Female patients of childbearing potential must have a negative Human Chorionic Gonadotropin ("HCG") pregnancy test taken during the screening visit and confirmed prior to the Study Treatment
Female patients of childbearing potential must be willing to use 2 methods of birth control (i.e.: oral contraceptive, pills, diaphragm or condoms) or be surgically sterile, or abstain from heterosexual activity for two weeks after the Study Treatment. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year
Are not candidates for cystectomy on medical grounds or refuse radical cystectomy
At least five of six doses of an initial induction course, plus at least two of six doses of a second induction course
Have satisfactory bladder function. Ability to retain Study Drug for a minimum of 1 hour

Exclusion Criteria

Past or current muscle invasive (i.e.: T2, T3, T4) or metastatic urothelial carcinoma
Has concurrent extravesical (i.e.: urethra, ureter, renal pelvis, prostate or prostatic ducts) non-muscle invasive transitional cell carcinoma of the urothelium. (confirmed by staging to exclude extravesical disease, which may include radiological imaging and/or biopsy) within 3 months of enrollment
If previous work up occurred more than 3 months prior to enrollment, staging
for extravesical disease must be repeated prior to enrolment in order to
determine eligibility
Active gross hematuria
Have a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer or localized prostate cancer under active surveillance with Gleason 6 disease. A history of prostate cancer that was treated with definitive intent (surgically or through radiation therapy) is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower; prostate-specific antigen (PSA) undetectable for 2 years while off androgen deprivation therapy or no more than 2 consecutive rising PSAs
Have a history or current evidence of any condition, therapy, surgery or laboratory abnormality that, in the opinion of the PI, might confound the results of the Study, interfere with the patient's participation in the Study, or is not in the best interest of the patient to participate
Currently receiving treatment with a prohibited concomitant therapy (refer to 12.2.1, Prohibited Medications)
Participated in a study with an investigational agent or device within 1 month from the first dose of current Study treatment
Prior treatment with an intravesical chemotherapeutic agent within 1 month of the first dose of current Study Drug, with the exception of a single perioperative dose of chemotherapy immediately post-TURBT (not considered treatment)
Have an active infection requiring systemic therapy, including active or intractable Urinary Tract Infection ("UTI"), not resolved prior to the procedure
Has any contraindication to general or spinal anesthesia
Is pregnant or breastfeeding within the projected duration of the Study, starting with the screening visit through to two weeks following the second TLD-1433 instillation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note